References

Chiaretti, Sabina, Matteo Leoncin, Loredana Elia, et al. 2024. “Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820.” Blood 144 (Supplement 1): 835–35. https://doi.org/10.1182/blood-2024-207892.

DeAngelo, Daniel J., Daohai Yu, Jeffrey L. Johnson, et al. 2007. “Nelarabine Induces Complete Remissions in Adults with Relapsed or Refractory t-Lineage Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Cancer and Leukemia Group b Study 19801.” Blood 109 (12): 5136–42. https://doi.org/10.1182/blood-2006-11-056754.

Hormann, Femke M., and Sean G. Rudd. 2025. “Nelarabine in t-Cell Acute Lymphoblastic Leukemia: Intracellular Metabolism and Molecular Mode-of-Action.” Leukemia 39 (3): 531–42. https://doi.org/10.1038/s41375-025-02529-2.

Huguet, Françoise, Sylvie Chevret, Thibaut Leguay, et al. 2018. “Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.” Journal of Clinical Oncology 36 (24): 2514–23. https://doi.org/10.1200/jco.2017.76.8192.

Jabbour, Elias, Nicholas J Short, Nitin Jain, et al. 2023. “Ponatinib and Blinatumomab for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A US, Single-Centre, Single-Arm, Phase 2 Trial.” The Lancet Haematology 10 (1): e24–34. https://doi.org/10.1016/s2352-3026(22)00319-2.

Jabbour, Elias, Nicholas J Short, Jayastu Senapati, et al. 2023. “Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or Without Blinatumomab, in the Subgroup of Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative b-Cell Acute Lymphocytic Leukaemia: Long-Term Results of an Open-Label Phase 2 Trial.” The Lancet Haematology 10 (6): e433–44. https://doi.org/10.1016/s2352-3026(23)00073-x.

Kantarjian, Hagop M., Susan O’Brien, Terry L. Smith, et al. 2000. “Results of Treatment with Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia.” Journal of Clinical Oncology 18 (3): 547–47. https://doi.org/10.1200/jco.2000.18.3.547.

Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.

Lazarus, H. M. 2006. “Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia at Diagnosis: Results from the International ALL Trial MRC UKALL XII/ECOG E2993.” Blood 108 (2): 465–72. https://doi.org/10.1182/blood-2005-11-4666.

Petersdorf, SH, KJ Kopecky, DR Head, et al. 2001. “Comparison of the L10M Consolidation Regimen to an Alternative Regimen Including Escalating Methotrexate/l-Asparaginase for Adult Acute Lymphoblastic Leukemia: A Southwest Oncology Group Study.” Leukemia 15 (2): 208–16. https://doi.org/10.1038/sj.leu.2402006.

Rowe, J. M. 2005. “Induction Therapy for Adults with Acute Lymphoblastic Leukemia: Results of More Than 1500 Patients from the International ALL Trial: MRC UKALL XII/ECOG E2993.” Blood 106 (12): 3760–67. https://doi.org/10.1182/blood-2005-04-1623.

Savino, Angela Maria, Sara Isabel Fernandes, Orianne Olivares, et al. 2020. “Metabolic Adaptation of Acute Lymphoblastic Leukemia to the Central Nervous System Microenvironment Depends on Stearoyl-CoA Desaturase.” Nature Cancer 1 (10): 998–1009. https://doi.org/10.1038/s43018-020-00115-2.

Stock, Wendy, Selina M. Luger, Anjali S. Advani, et al. 2019. “A Pediatric Regimen for Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Results of CALGB 10403.” Blood 133 (14): 1548–59. https://doi.org/10.1182/blood-2018-10-881961.

Whiteley, Andrew E., Trevor T. Price, Gaia Cantelli, and Dorothy A. Sipkins. 2021. “Leukaemia: A Model Metastatic Disease.” Nature Reviews Cancer 21 (7): 461–75. https://doi.org/10.1038/s41568-021-00355-z.

Yao, Hisayuki, Trevor T. Price, Gaia Cantelli, et al. 2018. “Leukaemia Hijacks a Neural Mechanism to Invade the Central Nervous System.” Nature 560 (7716): 55–60. https://doi.org/10.1038/s41586-018-0342-5.